Faculty & Staff at TUC

Thomas KL, Muzyk AJ. Surveys of substance use disorders education in US pharmacy programs. Mental Health Clinician 2018;8(1):14–17.

Van Dyke P, Thomas KL. Concomitant calcium channel blocker and antipsychotic therapy in patients with schizophrenia: Efficacy analysis of the CATIE-Sz phase 1 data. Ann Clin Psychiatry. 2017;29(4):e1-e11.

Thomas KL, Doroudgar, S. Lithium, In: Ray SD, Editor. Side Effects of Drugs Annual: A worldwide yearly survey of new data in adverse drug reactions, Vol. 39, pp. 23-30, Elsevier: Cambridge, 2017.

Dopheide JA, Bostwick JR, Goldstone LW, Thomas K, Nemire R, Gable KN, Cates M, Caballero J, Smith T, Bainbridge J. Curriculum in Psychiatry and Neurology for Pharmacy Programs. AJPE. 2017;81(7):Article 5925.

Muzyk AJ, Peedin E, Lipetzky J, Parker H, McEachern MP, Thomas K. Substance use education in US schools of pharmacy: A systematic review of the literature. Subst Abus. 2017;38(4):455–463.

Thomas K, Malcolm B, Lastra D. Psilocybin-assisted therapy: a review of a novel treatment for psychiatric disorders. J Psychoactive Drugs. 2017;49(5):446-455.

Doroudgar S, Chuang HM, Perry PJ, Thomas K, Bohnert K, Canedo J. Driving performance comparing older versus younger drivers. Traffic Inj Prev. 2017;18(1):41-46.

Ray SD, Thomas KL, Kisor DF. ADRs, ADEs and SEDs: A Bird’s Eye View, In Side Effects of Drugs Annual: A worldwide yearly survey of new data in adverse drug reactions, Vol. 38, pp. xxvii-xli, Elsevier: Cambridge, 2016.

Maroney ME, Liu MT, Smith T, Thomas KL. Lithium, In: Ray SD, Editor. Side Effects of Drugs Annual: A worldwide yearly survey of new data in adverse drug reactions, Vol. 38, pp. 21-28, Elsevier: Cambridge, 2016.

Thomas K, Canedo J, Perry PJ, et al. Effects of valerian on subjective sedation, field sobriety testing and driving simulator performance. Accid Anal Prev. 2016;92:240-244.

Thomas KL, La A, Punia S, Doroudgar S, Perry P.  Valproic acid-induced hyperammonemia and minimal hepatic encephalopathy prevalence among psychiatric inpatients. Annals of Clinical Psychiatry. 2016;28(1):37-42.

Nguyen L, Thomas KL, Lucke-wold BP, Cavendish JZ, Crowe MS, Matsumoto RR. Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders. Pharmacol Ther. 2016;159:1-22.

Perry PJ, Fredriksen K, Chew S, Ip EJ, Lopes I, Doroudgar S, Thomas K. The Effects of Dextromethorphan on Driving Performance and the Standardized Field Sobriety Test. J Forensic Sci. 2015;60(5):1258-62. 

Thomas KL, Jiang Y, McCombs JS.  Clozapine revisited: Impact of clozapine vs olanzapine on health care use by schizophrenia patients on Medicaid. Ann Clin Psychiatry. 2015;27(2):90-9.

English BA, Thomas KL, Johnstone J, Bazih A, Gertsik L, Ereshefsky L.  Use of translational pharmacodynamic biomarkers in early-phase clinical studies for schizophrenia. Biomark Med. 2014;8(1):29-49. 

English BA, Thomas KL, Gertsik L, Ereshefsky L. Early phase drug development strategies to inform decision making and the viability of novel CNS compounds in schizophrenia. JCS. 2013;5(4):34-9.

English BA, Ereshefsky L, Thomas KL, Jhee S. Improving Transition of Investigational Medicines in Alzheimer’s Disease from Phase 1 to Phase 2. JCS. 2013;5(1):52-9.

Bly MJ, Bishop JR, Thomas KL, Ellingrod VL. P-glycoprotein (PGP) Polymorphisms and Sexual Dysfunction in Female Patients with Depression and SSRI-Associated Sexual Side Effects. J Sex Marital Ther. 2013;39(3):280-88.

Thomas KL, Ellingrod VL, Bishop JR, Keiser MJ. A Pilot Study of the Pharmacodynamic Impact of SSRI Drug Selection and Beta-1 Receptor Genotype (ADRB1) on Cardiac Vital Signs in Depressed Patients: A Novel Pharmacogenetic Approach. Psychopharmacol Bull. 2010;43(1):11-22.

Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, Jensen NH, Kuijer MB, Matos RC, Tran TB, Whaley R, Glennon RA, Hert J, Thomas KL, Edwards DD, Shoichet BK, Roth BL. Predicting new molecular targets for known drugs. Nature. 2009;462(7270):175-81.

Ellingrod VL, Bishop JR, Thomas KL. Pharmacogenomics of Psychiatry. In Pharmacogenomics: Applications to Patient Care, Second Edition. ACCP: Kansas City, 2009.

Thomas KL, Ellingrod VL. Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions. Pharmacotherapy. 2009;29(7):822-31.